Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Age-specific characteristics of neutrophilic dermatoses and neutrophilic diseases in children.
Journal of the European Academy of Dermatology and Venereology : JEADV·2019
[Hypocomplementemic urticarial vasculitis].
La Revue de medecine interne·2017
Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses.
The British journal of dermatology·2015
Necroptosis is preceded by nuclear translocation of the signaling proteins that induce it.
Cell death and differentiation·2015
Inverted duplication with deletion: first interstitial case suggesting a novel undescribed mechanism of formation.
American journal of medical genetics. Part A·2014
Comparison of freehand-navigated and aiming device-navigated targeting of liver lesions.
The international journal of medical robotics + computer assisted surgery : MRCAS·2013
[Histoid leprosy with erythema nodosum leprosum].
Acta leprologica·2004
Is soil an alternative source of leprosy infection?
Acta leprologica·2002
[Immuno-allergic accidents with rifamipcin].
Acta leprologica·2002
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026